Davis's Drug Guide
Tri–Legest–21
Phase I
norethindrone 1 mg + ethinyl estradiol 20 mcg
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Tri–Legest–21." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. www.drugguide.com/ddo/view/Davis-Drug-Guide/109996/all/Tri_Legest_21.
Vallerand AHA, Sanoski CAC, Quiring CC. Tri–Legest–21. Davis's Drug Guide. F.A. Davis Company; 2023. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109996/all/Tri_Legest_21. Accessed June 10, 2023.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Tri–Legest–21. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109996/all/Tri_Legest_21
Vallerand AHA, Sanoski CAC, Quiring CC. Tri–Legest–21 [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2023 June 10]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109996/all/Tri_Legest_21.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tri–Legest–21
ID - 109996
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109996/all/Tri_Legest_21
PB - F.A. Davis Company
ET - 18
DB - Davis's Drug Guide
DP - Unbound Medicine
ER -